Ran Zheng
Direktor/Vorstandsmitglied bei CARIBOU BIOSCIENCES, INC.
Vermögen: - $ am 30.04.2024
Aktive Positionen von Ran Zheng
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 24.09.2021 | - |
| Independent Dir/Board Member | 24.09.2021 | - | |
| Landmark Bio PBLLC | Direktor/Vorstandsmitglied | 01.03.2021 | - |
| Vorstandsvorsitzender | 01.03.2021 | - |
Karriereverlauf von Ran Zheng
Ehemalige bekannte Positionen von Ran Zheng
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ORCHARD THERAPEUTICS PLC | Technik-/Wissenschafts-/F&E-Leiter | 18.03.2019 | 01.02.2021 |
| AMGEN INC. | Corporate Officer/Principal | - | - |
Ausbildung von Ran Zheng
| Beijing Forestry University | Undergraduate Degree |
| University of Minnesota | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| Vereinigtes Königreich | 2 |
| China | 2 |
Operativ
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
| Landmark Bio PBLLC |
